U.S. markets close in 2 hours 34 minutes
  • S&P 500

    4,398.92
    +44.73 (+1.03%)
     
  • Dow 30

    34,305.75
    +385.91 (+1.14%)
     
  • Nasdaq

    14,870.03
    +123.63 (+0.84%)
     
  • Russell 2000

    2,218.23
    +32.05 (+1.47%)
     
  • Crude Oil

    71.97
    +1.48 (+2.10%)
     
  • Gold

    1,779.00
    +0.80 (+0.04%)
     
  • Silver

    22.92
    +0.31 (+1.39%)
     
  • EUR/USD

    1.1736
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.3130
    -0.0110 (-0.83%)
     
  • GBP/USD

    1.3653
    -0.0011 (-0.08%)
     
  • USD/JPY

    109.6150
    +0.3950 (+0.36%)
     
  • BTC-USD

    42,988.54
    +1,072.09 (+2.56%)
     
  • CMC Crypto 200

    1,076.43
    +35.95 (+3.45%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Why Investors Should Like BioNTech's Latest Deal With Gilead

·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BioNTech (NASDAQ: BNTX) has begun to spend some of the cash generated by its COVID-19 vaccine. The German drugmaker recently announced an agreement with Gilead Sciences (NASDAQ: GILD) to acquire a research program and a manufacturing site. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what investors should like about BioNTech's deal with Gilead.